메뉴 건너뛰기




Volumn 8, Issue 6, 2013, Pages

Resistance Mutations outside the Integrase Coding Region Have an Effect on Human Immunodeficiency Virus Replicative Fitness but Do Not Affect Its Susceptibility to Integrase Strand Transfer Inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; DOLUTEGRAVIR; ELVITEGRAVIR; EMTRICITABINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INDINAVIR; INTEGRASE; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEIN NCP7; PROTEIN P1; PROTEIN P2; PROTEIN P6; PROTEINASE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

EID: 84878915307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065631     Document Type: Article
Times cited : (10)

References (69)
  • 1
    • 0027531918 scopus 로고
    • Pathogenesis of human immunodeficiency virus infection
    • Levy JA, (1993) Pathogenesis of human immunodeficiency virus infection. MicrobiolRev 57: 183-289.
    • (1993) MicrobiolRev , vol.57 , pp. 183-289
    • Levy, J.A.1
  • 2
    • 0034723439 scopus 로고    scopus 로고
    • Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
    • Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, et al. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287: 646-650.
    • (2000) Science , vol.287 , pp. 646-650
    • Hazuda, D.J.1    Felock, P.2    Witmer, M.3    Wolfe, A.4    Stillmock, K.5
  • 3
    • 55049092459 scopus 로고    scopus 로고
    • HIV type 1 integrase inhibitors: from basic research to clinical implications
    • Jegede O, Babu J, Di Santo R, McColl DJ, Weber J, et al. (2008) HIV type 1 integrase inhibitors: from basic research to clinical implications. AIDS Rev 10: 172-189.
    • (2008) AIDS Rev , vol.10 , pp. 172-189
    • Jegede, O.1    Babu, J.2    Di Santo, R.3    McColl, D.J.4    Weber, J.5
  • 4
    • 73549123203 scopus 로고    scopus 로고
    • Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy
    • McColl DJ, Chen X, (2010) Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral research 85: 101-118.
    • (2010) Antiviral Research , vol.85 , pp. 101-118
    • McColl, D.J.1    Chen, X.2
  • 5
    • 52449097240 scopus 로고    scopus 로고
    • Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection
    • Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, et al. (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. Journal of medicinal chemistry 51: 5843-5855.
    • (2008) Journal of Medicinal Chemistry , vol.51 , pp. 5843-5855
    • Summa, V.1    Petrocchi, A.2    Bonelli, F.3    Crescenzi, B.4    Donghi, M.5
  • 6
    • 33644863638 scopus 로고    scopus 로고
    • Novel HIV-1 integrase inhibitors derived from quinolone antibiotics
    • Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, et al. (2006) Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. JMedChem 49: 1506-1508.
    • (2006) JMedChem , vol.49 , pp. 1506-1508
    • Sato, M.1    Motomura, T.2    Aramaki, H.3    Matsuda, T.4    Yamashita, M.5
  • 7
    • 84878924070 scopus 로고    scopus 로고
    • Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients
    • Zolopa A, Gallant J, Cohen C, Sax P, Dejesus E, et al. (2012) Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients. Journal of the International AIDS Society 15: 18219.
    • (2012) Journal of the International AIDS Society , vol.15 , pp. 18219
    • Zolopa, A.1    Gallant, J.2    Cohen, C.3    Sax, P.4    Dejesus, E.5
  • 9
    • 84874411899 scopus 로고    scopus 로고
    • Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
    • Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, et al. (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet.
    • (2013) Lancet
    • Raffi, F.1    Rachlis, A.2    Stellbrink, H.J.3    Hardy, W.D.4    Torti, C.5
  • 12
    • 37849002059 scopus 로고    scopus 로고
    • Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)
    • Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, et al. (2008) Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). JVirol 82: 764-774.
    • (2008) JVirol , vol.82 , pp. 764-774
    • Shimura, K.1    Kodama, E.2    Sakagami, Y.3    Matsuzaki, Y.4    Watanabe, W.5
  • 13
    • 55249105017 scopus 로고    scopus 로고
    • Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors
    • Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, et al. (2008) Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. Journal of Virology 82: 10366-10374.
    • (2008) Journal of Virology , vol.82 , pp. 10366-10374
    • Goethals, O.1    Clayton, R.2    Van Ginderen, M.3    Vereycken, I.4    Wagemans, E.5
  • 14
    • 84856111536 scopus 로고    scopus 로고
    • In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4
    • Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, et al. (2012) In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral research 93: 288-296.
    • (2012) Antiviral Research , vol.93 , pp. 288-296
    • Margot, N.A.1    Hluhanich, R.M.2    Jones, G.S.3    Andreatta, K.N.4    Tsiang, M.5
  • 15
    • 40549125135 scopus 로고    scopus 로고
    • Resistance and cross resistance to fist generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137)
    • McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, et al. (2007) Resistance and cross resistance to fist generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antiviral Therapy 12: S11.
    • (2007) Antiviral Therapy , vol.12
    • McColl, D.J.1    Fransen, S.2    Gupta, S.3    Parkin, N.4    Margot, N.5
  • 16
    • 77749267991 scopus 로고    scopus 로고
    • Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial
    • Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, et al. (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. JInfectDis 201: 814-822.
    • (2010) JInfectDis , vol.201 , pp. 814-822
    • Zolopa, A.R.1    Berger, D.S.2    Lampiris, H.3    Zhong, L.4    Chuck, S.L.5
  • 17
    • 78650640149 scopus 로고    scopus 로고
    • Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates
    • Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, et al. (2011) Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrobial Agents and Chemotherapy 55: 321-325.
    • (2011) Antimicrobial Agents and Chemotherapy , vol.55 , pp. 321-325
    • van Wesenbeeck, L.1    Rondelez, E.2    Feyaerts, M.3    Verheyen, A.4    van der Borght, K.5
  • 18
    • 84856226017 scopus 로고    scopus 로고
    • Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
    • van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, et al. (2012) Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet infectious diseases 12: 111-118.
    • (2012) The Lancet Infectious Diseases , vol.12 , pp. 111-118
    • van Lunzen, J.1    Maggiolo, F.2    Arribas, J.R.3    Rakhmanova, A.4    Yeni, P.5
  • 19
    • 84863393356 scopus 로고    scopus 로고
    • Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir
    • Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, et al. (2012) Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. Journal of Virology 86: 2696-2705.
    • (2012) Journal of Virology , vol.86 , pp. 2696-2705
    • Quashie, P.K.1    Mesplede, T.2    Han, Y.S.3    Oliveira, M.4    Singhroy, D.N.5
  • 20
    • 80155188567 scopus 로고    scopus 로고
    • Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir
    • Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, et al. (2011) Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. The Journal of infectious diseases 204: 1811-1815.
    • (2011) The Journal of Infectious Diseases , vol.204 , pp. 1811-1815
    • Canducci, F.1    Ceresola, E.R.2    Boeri, E.3    Spagnuolo, V.4    Cossarini, F.5
  • 21
    • 0001769435 scopus 로고    scopus 로고
    • HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution
    • In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F et al., editors, Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory
    • Quinones-Mateu ME, Arts EJ (2001) HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F et al., editors. HIV Sequence Compendium 2001. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory. 134-170.
    • (2001) HIV Sequence Compendium 2001 , pp. 134-170
    • Quinones-Mateu, M.E.1    Arts, E.J.2
  • 22
    • 0036971250 scopus 로고    scopus 로고
    • Fitness of drug resistant HIV-1: methodology and clinical implications
    • Quinones-Mateu ME, Arts EJ, (2002) Fitness of drug resistant HIV-1: methodology and clinical implications. Drug ResistUpdat 5: 224-233.
    • (2002) Drug ResistUpdat , vol.5 , pp. 224-233
    • Quinones-Mateu, M.E.1    Arts, E.J.2
  • 23
    • 30644462096 scopus 로고    scopus 로고
    • Virus fitness: concept, quantification, and application to HIV population dynamics
    • Quinones-Mateu ME, Arts EJ, (2006) Virus fitness: concept, quantification, and application to HIV population dynamics. Current Topics in Microbiology and Immunology 299: 83-140.
    • (2006) Current Topics in Microbiology and Immunology , vol.299 , pp. 83-140
    • Quinones-Mateu, M.E.1    Arts, E.J.2
  • 24
    • 0035141001 scopus 로고    scopus 로고
    • Implications of antiretroviral resistance on viral fitness
    • Nijhuis M, Deeks S, Boucher C, (2001) Implications of antiretroviral resistance on viral fitness. CurrOpinInfectDis 14: 23-28.
    • (2001) CurrOpinInfectDis , vol.14 , pp. 23-28
    • Nijhuis, M.1    Deeks, S.2    Boucher, C.3
  • 25
    • 84864125870 scopus 로고    scopus 로고
    • Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo
    • Fransen S, Gupta S, Frantzell A, Petropoulos CJ, Huang W, (2012) Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. Journal of Virology 86: 7249-7255.
    • (2012) Journal of Virology , vol.86 , pp. 7249-7255
    • Fransen, S.1    Gupta, S.2    Frantzell, A.3    Petropoulos, C.J.4    Huang, W.5
  • 26
    • 70350666377 scopus 로고    scopus 로고
    • Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways
    • Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, et al. (2009) Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. Journal of Virology 83: 11440-11446.
    • (2009) Journal of Virology , vol.83 , pp. 11440-11446
    • Fransen, S.1    Gupta, S.2    Danovich, R.3    Hazuda, D.4    Miller, M.5
  • 28
    • 70349272200 scopus 로고    scopus 로고
    • Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes
    • Quercia R, Dam E, Perez-Bercoff D, Clavel F, (2009) Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. Journal of Virology 83: 10245-10249.
    • (2009) Journal of Virology , vol.83 , pp. 10245-10249
    • Quercia, R.1    Dam, E.2    Perez-Bercoff, D.3    Clavel, F.4
  • 29
    • 77957310350 scopus 로고    scopus 로고
    • Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness
    • Hu Z, Kuritzkes DR, (2010) Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. Journal of Acquired Immune Deficiency Syndromes 55: 148-155.
    • (2010) Journal of Acquired Immune Deficiency Syndromes , vol.55 , pp. 148-155
    • Hu, Z.1    Kuritzkes, D.R.2
  • 30
    • 77956109186 scopus 로고    scopus 로고
    • Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors
    • Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, et al. (2010) Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrobial Agents and Chemotherapy 54: 3938-3948.
    • (2010) Antimicrobial Agents and Chemotherapy , vol.54 , pp. 3938-3948
    • Ceccherini-Silberstein, F.1    Van Baelen, K.2    Armenia, D.3    Trignetti, M.4    Rondelez, E.5
  • 32
    • 62149093020 scopus 로고    scopus 로고
    • The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
    • Delelis O, Malet I, Na L, Tchertanov L, Calvez V, et al. (2009) The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Research 37: 1193-1201.
    • (2009) Nucleic Acids Research , vol.37 , pp. 1193-1201
    • Delelis, O.1    Malet, I.2    Na, L.3    Tchertanov, L.4    Calvez, V.5
  • 33
    • 70349337790 scopus 로고    scopus 로고
    • Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure
    • Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos CJ, et al. (2009) Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrobial Agents and Chemotherapy 53: 4522-4524.
    • (2009) Antimicrobial Agents and Chemotherapy , vol.53 , pp. 4522-4524
    • Fransen, S.1    Karmochkine, M.2    Huang, W.3    Weiss, L.4    Petropoulos, C.J.5
  • 34
    • 70350156722 scopus 로고    scopus 로고
    • The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy
    • Ferns RB, Kirk S, Bennett J, Cook PM, Williams I, et al. (2009) The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 23: 2159-2164.
    • (2009) AIDS , vol.23 , pp. 2159-2164
    • Ferns, R.B.1    Kirk, S.2    Bennett, J.3    Cook, P.M.4    Williams, I.5
  • 35
    • 84856247092 scopus 로고    scopus 로고
    • Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing
    • Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, et al. (2012) Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. The Journal of infectious diseases 205: 557-567.
    • (2012) The Journal of Infectious Diseases , vol.205 , pp. 557-567
    • Armenia, D.1    Vandenbroucke, I.2    Fabeni, L.3    Van Marck, H.4    Cento, V.5
  • 36
    • 84878886967 scopus 로고    scopus 로고
    • Effect of primary elvitegravir resistance mutations in HIV-1 integrase on drug susceptibility and viral replication fitness
    • Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, et al. (2012) Effect of primary elvitegravir resistance mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antivir Ther 17: A11.
    • (2012) Antivir Ther , vol.17
    • Abram, M.E.1    Hluhanich, R.M.2    Goodman, D.D.3    Andreatta, K.N.4    Margot, N.A.5
  • 37
    • 52749097450 scopus 로고    scopus 로고
    • Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increase resistance
    • Sitges, Spain
    • Goodman D, Hluhanich R, Waters J, Margot N, Fransen S, et al. (2008) Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increase resistance. XVII International HIV Drug Resistance Workshop, Sitges, Spain.
    • (2008) XVII International HIV Drug Resistance Workshop
    • Goodman, D.1    Hluhanich, R.2    Waters, J.3    Margot, N.4    Fransen, S.5
  • 38
    • 84873649469 scopus 로고    scopus 로고
    • Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness
    • Mesplede T, Quashie P, Oliveira M, Underwood M, Wang R, et al. (2012) Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness. Journal of the International AIDS Society 15: 18113.
    • (2012) Journal of the International AIDS Society , vol.15 , pp. 18113
    • Mesplede, T.1    Quashie, P.2    Oliveira, M.3    Underwood, M.4    Wang, R.5
  • 39
    • 84874039772 scopus 로고    scopus 로고
    • Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
    • Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, et al. (2013) Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22.
    • (2013) Retrovirology , vol.10 , pp. 22
    • Mesplede, T.1    Quashie, P.K.2    Osman, N.3    Han, Y.4    Singhroy, D.N.5
  • 41
    • 69449101785 scopus 로고    scopus 로고
    • Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
    • Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, et al. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374: 796-806.
    • (2009) Lancet , vol.374 , pp. 796-806
    • Lennox, J.L.1    DeJesus, E.2    Lazzarin, A.3    Pollard, R.B.4    Madruga, J.V.5
  • 42
    • 84894019450 scopus 로고    scopus 로고
    • Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients
    • Rockstroh J, Dejesus E, Henry K, Molina J, Gathe J, et al. (2012) Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients. Journal of the International AIDS Society 15: 18220.
    • (2012) Journal of the International AIDS Society , vol.15 , pp. 18220
    • Rockstroh, J.1    Dejesus, E.2    Henry, K.3    Molina, J.4    Gathe, J.5
  • 43
    • 47949114939 scopus 로고    scopus 로고
    • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
    • Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, et al. (2008) Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. NEnglJMed 359: 355-365.
    • (2008) NEnglJMed , vol.359 , pp. 355-365
    • Cooper, D.A.1    Steigbigel, R.T.2    Gatell, J.M.3    Rockstroh, J.K.4    Katlama, C.5
  • 44
    • 63449110982 scopus 로고    scopus 로고
    • Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss
    • Dam E, Quercia R, Glass B, Descamps D, Launay O, et al. (2009) Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoSPathog 5: e1000345.
    • (2009) PLoSPathog , vol.5
    • Dam, E.1    Quercia, R.2    Glass, B.3    Descamps, D.4    Launay, O.5
  • 46
    • 77951213245 scopus 로고    scopus 로고
    • Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance
    • Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, et al. (2010) Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. AntimicrobAgents Chemother 54: 1973-1980.
    • (2010) AntimicrobAgents Chemother , vol.54 , pp. 1973-1980
    • Gupta, S.1    Fransen, S.2    Paxinos, E.E.3    Stawiski, E.4    Huang, W.5
  • 47
    • 52049107430 scopus 로고    scopus 로고
    • Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and -independent mechanisms
    • Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCormick S, et al. (2008) Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and-independent mechanisms. JBiolChem 283: 22222-22232.
    • (2008) JBiolChem , vol.283 , pp. 22222-22232
    • Ehteshami, M.1    Beilhartz, G.L.2    Scarth, B.J.3    Tchesnokov, E.P.4    McCormick, S.5
  • 48
    • 73649137500 scopus 로고    scopus 로고
    • The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates
    • Buzon MJ, Dalmau J, Puertas MC, Puig J, Clotet B, et al. (2010) The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 24: 17-25.
    • (2010) AIDS , vol.24 , pp. 17-25
    • Buzon, M.J.1    Dalmau, J.2    Puertas, M.C.3    Puig, J.4    Clotet, B.5
  • 49
    • 79960330731 scopus 로고    scopus 로고
    • Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy
    • Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, et al. (2011) Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrobial Agents and Chemotherapy 55: 3729-3742.
    • (2011) Antimicrobial Agents and Chemotherapy , vol.55 , pp. 3729-3742
    • Weber, J.1    Vazquez, A.C.2    Winner, D.3    Rose, J.D.4    Wylie, D.5
  • 50
    • 79960315643 scopus 로고    scopus 로고
    • Novel anti-HIV-1 screening system based on intact recombinant viruses expressing synthetic firefly and renilla luminescent proteins
    • Weber J, Quinones-Mateu ME, (2007) Novel anti-HIV-1 screening system based on intact recombinant viruses expressing synthetic firefly and renilla luminescent proteins. AntivirTher 12: S155.
    • (2007) AntivirTher , vol.12
    • Weber, J.1    Quinones-Mateu, M.E.2
  • 51
    • 33745158157 scopus 로고
    • A simple method of estimating fifty percent endpoints
    • Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. AmJHyg 27 493-497.
    • (1938) AmJHyg , vol.27 , pp. 493-497
    • Reed, L.J.1    Muench, H.2
  • 52
    • 79953049919 scopus 로고    scopus 로고
    • Human Immunodeficiency Virus Type 1 Resistance or Cross-resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides
    • Selhorst P, Vazquez AC, Terrazas-Aranda K, Michiels J, Vereecken K, et al. (2011) Human Immunodeficiency Virus Type 1 Resistance or Cross-resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides. AntimicrobAgents Chemother 55: 1403-1413.
    • (2011) AntimicrobAgents Chemother , vol.55 , pp. 1403-1413
    • Selhorst, P.1    Vazquez, A.C.2    Terrazas-Aranda, K.3    Michiels, J.4    Vereecken, K.5
  • 53
    • 0033803642 scopus 로고    scopus 로고
    • A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression
    • Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, et al. (2000) A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. JVirol 74: 9222-9233.
    • (2000) JVirol , vol.74 , pp. 9222-9233
    • Quinones-Mateu, M.E.1    Ball, S.C.2    Marozsan, A.J.3    Torre, V.S.4    Albright, J.L.5
  • 54
    • 33745886803 scopus 로고    scopus 로고
    • Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness
    • Weber J, Weberova J, Carobene M, Mirza M, Martinez-Picado J, et al. (2006) Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods 136: 102-117.
    • (2006) J Virol Methods , vol.136 , pp. 102-117
    • Weber, J.1    Weberova, J.2    Carobene, M.3    Mirza, M.4    Martinez-Picado, J.5
  • 55
    • 0042405174 scopus 로고    scopus 로고
    • A Novel TaqMan Real-Time PCR Assay to Estimate ex vivo Human Immunodeficiency Virus type 1 Fitness in the Era of Multi-Target (pol and env) Antiretroviral Therapy
    • Weber J, Rangel HR, Chakraborty B, Tadele M, Martinez MA, et al. (2003) A Novel TaqMan Real-Time PCR Assay to Estimate ex vivo Human Immunodeficiency Virus type 1 Fitness in the Era of Multi-Target (pol and env) Antiretroviral Therapy. Journal of General Virology 84: 2217-2228.
    • (2003) Journal of General Virology , vol.84 , pp. 2217-2228
    • Weber, J.1    Rangel, H.R.2    Chakraborty, B.3    Tadele, M.4    Martinez, M.A.5
  • 56
    • 67651015445 scopus 로고    scopus 로고
    • A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates
    • Dudley DM, Gao Y, Nelson KN, Henry KR, Nankya I, et al. (2009) A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques 46: 458-467.
    • (2009) Biotechniques , vol.46 , pp. 458-467
    • Dudley, D.M.1    Gao, Y.2    Nelson, K.N.3    Henry, K.R.4    Nankya, I.5
  • 57
    • 77953789703 scopus 로고    scopus 로고
    • Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients
    • Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, et al. (2010) Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients. AntimicrobAgents Chemother 54: 2910-2919.
    • (2010) AntimicrobAgents Chemother , vol.54 , pp. 2910-2919
    • Larrouy, L.1    Chazallon, C.2    Landman, R.3    Capitant, C.4    Peytavin, G.5
  • 58
    • 38049028352 scopus 로고    scopus 로고
    • N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance
    • Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, et al. (2007) N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoSMed 4: e335.
    • (2007) PLoSMed , vol.4
    • Yap, S.H.1    Sheen, C.W.2    Fahey, J.3    Zanin, M.4    Tyssen, D.5
  • 59
    • 59649106106 scopus 로고    scopus 로고
    • Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility
    • Ehteshami M, Gotte M, (2008) Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev 10: 224-235.
    • (2008) AIDS Rev , vol.10 , pp. 224-235
    • Ehteshami, M.1    Gotte, M.2
  • 60
    • 65549142692 scopus 로고    scopus 로고
    • Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase
    • Wilkinson TA, Januszyk K, Phillips ML, Tekeste SS, Zhang M, et al. (2009) Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. JBiolChem 284: 7931-7939.
    • (2009) JBiolChem , vol.284 , pp. 7931-7939
    • Wilkinson, T.A.1    Januszyk, K.2    Phillips, M.L.3    Tekeste, S.S.4    Zhang, M.5
  • 61
    • 77957875432 scopus 로고    scopus 로고
    • Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors
    • Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, et al. (2010) Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. The Journal of antimicrobial chemotherapy 65: 2305-2318.
    • (2010) The Journal of Antimicrobial Chemotherapy , vol.65 , pp. 2305-2318
    • Ceccherini-Silberstein, F.1    Malet, I.2    Fabeni, L.3    Dimonte, S.4    Svicher, V.5
  • 62
    • 84864007971 scopus 로고    scopus 로고
    • Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations
    • Winters MA, Lloyd RM Jr, Shafer RW, Kozal MJ, Miller MD, et al. (2012) Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PloS one 7: e40514.
    • (2012) PloS One , vol.7
    • Winters, M.A.1    Lloyd Jr., R.M.2    Shafer, R.W.3    Kozal, M.J.4    Miller, M.D.5
  • 64
    • 79955423458 scopus 로고    scopus 로고
    • A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase
    • Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, et al. (2011) A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nature genetics 43: 487-489.
    • (2011) Nature Genetics , vol.43 , pp. 487-489
    • Hinkley, T.1    Martins, J.2    Chappey, C.3    Haddad, M.4    Stawiski, E.5
  • 65
    • 34248364854 scopus 로고    scopus 로고
    • Epistasis between deleterious mutations and the evolution of recombination
    • Kouyos RD, Silander OK, Bonhoeffer S, (2007) Epistasis between deleterious mutations and the evolution of recombination. Trends in ecology & evolution 22: 308-315.
    • (2007) Trends in Ecology & Evolution , vol.22 , pp. 308-315
    • Kouyos, R.D.1    Silander, O.K.2    Bonhoeffer, S.3
  • 66
    • 77956641491 scopus 로고    scopus 로고
    • Fitness Epistasis and Constraints on Adaptation in a Human Immunodeficiency Virus Type 1 Protein Region
    • da SJ, Coetzer M, Nedellec R, Pastore C, Mosier DE (2010) Fitness Epistasis and Constraints on Adaptation in a Human Immunodeficiency Virus Type 1 Protein Region. Genetics.
    • (2010) Genetics
    • da, S.J.1    Coetzer, M.2    Nedellec, R.3    Pastore, C.4    Mosier, D.E.5
  • 68
    • 79953669224 scopus 로고    scopus 로고
    • Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1
    • Martinez JP, Bocharov G, Ignatovich A, Reiter J, Dittmar MT, et al. (2011) Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1. PloS one 6: e18375.
    • (2011) PloS One , vol.6
    • Martinez, J.P.1    Bocharov, G.2    Ignatovich, A.3    Reiter, J.4    Dittmar, M.T.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.